A medical device company founded by Danish businessman Thomas Sandgaard has admitted guilt in a massive healthcare fraud scheme and agreed to pay millions in fines, while Sandgaard himself remains in federal custody facing 15 criminal charges. The company, Zynex, acknowledged defrauding government healthcare programs and private insurers of hundreds of millions of dollars over an eight year period.
Zynex Admits to Massive Fraud Operation
The Colorado based medical equipment manufacturer Zynex has reached a criminal settlement with U.S. authorities after admitting to orchestrating a widespread fraud scheme that generated over five billion Danish kroner in revenue. According to the U.S. Department of Justice, the company systematically defrauded both public and private healthcare programs while misleading investors about its business practices.
Company Generated Billions Through Fraudulent Billing
Federal prosecutors revealed that Zynex generated approximately 873 million dollars between 2017 and 2025, with the majority of that revenue stemming from fraudulent activity. The company manufactured and distributed pain management and rehabilitation equipment, including small electrotherapy devices used by patients at home. However, prosecutors allege that Zynex routinely shipped massive quantities of medical supplies to customers who had neither requested nor approved them.
The scheme involved billing government healthcare programs and private insurers for equipment that was medically unnecessary and not covered by insurance. In many cases, patients received products they never authorized. This practice allowed Zynex to inflate its revenue dramatically while exploiting vulnerable individuals seeking relief from chronic pain.
Criminal Settlement Requires Financial Penalties and Reform
As part of the 66 page settlement agreement, Zynex must pay between five and 12.5 million dollars in fines, with the exact amount dependent on the company’s future earnings. That translates to roughly 32 million to 79 million Danish kroner. Additionally, the company agreed to forfeit all outstanding payment claims dating back to September 2025, a sum totaling approximately 100 million dollars.
U.S. Attorney Charles C. Calenda stated that the settlement reflects both the severity of the fraud and the significant behavioral changes implemented under new leadership. He emphasized that when new management confronts fraudulent practices, implements reforms, and cooperates fully with authorities, the government considers those actions when determining appropriate resolutions.
Founder Remains in Federal Custody
While Zynex negotiated its way out of a criminal trial, company founder Thomas Sandgaard faces a far more uncertain future. The Danish American entrepreneur remains in federal detention after being arrested by FBI agents in January, with local American media reporting that he was denied bail.
Fifteen Criminal Counts and Potential Prison Time
Sandgaard faces 15 separate criminal charges related to his alleged role in orchestrating the fraud scheme. His former second in command at Zynex was also arrested but has been released with an electronic monitoring device. According to court documents, Sandgaard was formally remanded to custody on January 26.
FBI Special Agent Ted E. Docks from the Boston field office stated that the arrests addressed allegations of defrauding the government and insurance companies of hundreds of millions of dollars while exploiting vulnerable patients seeking pain relief. The criminal investigation remains active as prosecutors continue building their case against both defendants.
Former Executive No Longer Connected to Company Operations
Zynex moved swiftly to distance itself from its founder after the charges became public. The company installed entirely new leadership in August of the previous year, months before Sandgaard’s arrest. Current management has emphasized that neither Sandgaard nor his co defendant maintains any role in company operations or decision making.
The new executive team has committed to breaking from past practices and rebuilding the organization around principles of transparency and compliance. This institutional separation proved crucial in allowing Zynex to negotiate a settlement rather than face prosecution as a corporate entity.
Rise and Fall of a Business Empire
Thomas Sandgaard’s journey from successful entrepreneur to federal defendant represents a dramatic reversal of fortune. He founded Zynex in 1996 and built it into a publicly traded company, achieving a Nasdaq listing in 2019 that initially generated substantial wealth.
Stock Market Success Preceded Regulatory Scrutiny
Following its public listing, Zynex appeared to thrive as a medical device manufacturer. The stock’s performance allowed Sandgaard to accumulate significant personal wealth, which he invested in high profile ventures including sports franchises. At its peak, the company’s market valuation reached approximately three billion Danish kroner.
However, warning signs emerged in December 2024 when Tricare, the U.S. military’s public health insurance program, terminated its support for Zynex products. The stock price immediately plummeted, cutting the company’s market value nearly in half. Over the following year, the decline accelerated dramatically as regulatory investigations intensified.
Company Value Evaporated Amid Investigation
By the time Zynex filed for bankruptcy protection, its market capitalization had collapsed to roughly 15 million kroner. That represented a catastrophic decline of more than 99 percent from peak valuation. The speed and magnitude of the collapse left investors reeling and raised questions about how such extensive fraud could operate undetected for years.
Sandgaard had already stepped down as chief executive before the bankruptcy filing, though he retained a substantial equity stake. The transition to new management began as regulatory pressure mounted and the company’s financial position deteriorated rapidly.
International Business Ventures and Sports Investments
Beyond his medical device business, Sandgaard cultivated a public profile through strategic investments in professional sports. These ventures brought him visibility in both Denmark and the United Kingdom, making his subsequent legal troubles particularly newsworthy across multiple countries.
Brief Ownership of English Football Club
In 2020, Sandgaard purchased Charlton Athletic, a football club competing in England’s third tier, for approximately 400 million Danish kroner. He financed the acquisition through proceeds from selling a portion of his Zynex holdings following the company’s Nasdaq listing. At the time, Sandgaard expressed confidence that the club could eventually be worth over one billion dollars if properly managed.
His tenure as owner lasted only three years and was marked by growing fan dissatisfaction. The club failed to secure promotion to a higher division despite Sandgaard’s investment. In his farewell message upon selling the club in 2023, he acknowledged that the experience had been bittersweet, characterized by both criticism and recognition.
Continued Stake in Danish Hockey Team
Sandgaard maintained business interests in Denmark through his investment vehicle Blue Ocean Investment ApS. Through this company, he owns 64.32 percent of Odense Bulldogs, a Danish ice hockey team. When news of the American charges broke, the hockey club issued a brief statement acknowledging awareness of the situation but emphasizing that it did not affect daily operations.
The club stated that it had no immediate comments beyond noting that Sandgaard’s legal troubles were not expected to impact the team’s functioning. This measured response reflected the organization’s attempt to maintain stability while its majority investor faced serious criminal allegations in another country.
New Management Commits to Corporate Reform
The leadership team that took control of Zynex in August has made rehabilitation of the company’s reputation and operations its central mission. These executives inherited an organization tainted by years of fraudulent practices and facing potential corporate prosecution.
Focus on Transparency and Compliance
Current CEO Steven Dyson acknowledged that previous business practices had overshadowed the genuine benefits that Zynex products provide to patients. He emphasized that customers and patients do experience real advantages from the company’s effective pain management devices. However, he stated that questionable billing and marketing practices had undermined confidence in the organization.
Dyson described a six month intensive effort to rebuild every aspect of company operations with emphasis on transparency, integrity, and regulatory compliance. The goal is ensuring that high quality products are supported by equally high quality business practices. This comprehensive reform effort factored significantly into prosecutors’ willingness to negotiate a settlement rather than pursue corporate criminal charges.
Settlement Represents Path Forward
Company officials characterized the criminal settlement as fulfillment of promises made when new leadership assumed control. Those commitments centered on acknowledging past wrongdoing, implementing systemic reforms, and cooperating fully with authorities. The new management team viewed accepting responsibility as essential to moving beyond the scandal.
The settlement allows Zynex to continue operating as a restructured entity while addressing the consequences of prior fraud. For patients who depend on the company’s pain management technology, this outcome preserves access to products that provide legitimate medical benefits despite the criminal activity that previously surrounded their distribution.
Implications for Patients and Healthcare System
The Zynex case highlights vulnerabilities in the American healthcare system that allow fraudulent billing practices to operate extensively before detection. The scheme allegedly ran for eight years, generating hundreds of millions in improper charges before authorities intervened.
Impact on Vulnerable Patient Population
Prosecutors emphasized that the fraud particularly harmed vulnerable individuals seeking relief from chronic pain. These patients often received unsolicited medical equipment that arrived without proper authorization or medical necessity determinations. Some faced unexpected bills for products they never requested. Others may have been pressured into accepting equipment to facilitate fraudulent billing.
The exploitation of people suffering from chronic pain represents an especially troubling aspect of the alleged scheme. These individuals often face limited treatment options and may be more susceptible to promises of relief. Using their medical needs as a vehicle for fraud compounds the harm beyond simple financial losses.
Systemic Weaknesses in Healthcare Payment Systems
The case also reveals how complex billing processes in American healthcare create opportunities for sustained fraud. When companies bill multiple payers including Medicare, Medicaid, and private insurers simultaneously, detecting patterns of improper charges becomes challenging. Each payer operates somewhat independently, making coordinated fraud difficult to identify until losses reach extraordinary levels.
Federal investigators likely spent years assembling evidence from multiple sources to build the case against Sandgaard and his co defendant. The lengthy investigation period suggests that traditional oversight mechanisms failed to detect the fraud during its most active years. This raises questions about whether systemic reforms beyond individual prosecutions are necessary.
Outstanding Questions and Next Steps
Despite the settlement with Zynex, numerous aspects of the case remain unresolved. Thomas Sandgaard’s criminal trial will determine his personal culpability and potential punishment, a process that could extend for months or years.
Criminal Proceedings Continue for Individual Defendants
The charges against Sandgaard and his former deputy represent separate legal proceedings from the corporate settlement. Both men face potential prison sentences if convicted on the counts filed against them. Federal healthcare fraud convictions often result in substantial incarceration periods, particularly in cases involving hundreds of millions of dollars.
Defense attorneys will likely challenge various aspects of the prosecution’s case, including evidence admissibility, the scope of alleged criminal conduct, and their clients’ personal knowledge of improper billing practices. These legal battles will unfold in federal court over an extended timeline.
Potential Additional Civil and Regulatory Actions
Beyond criminal prosecution, the case may generate civil litigation from investors, patients, and insurance companies seeking to recover losses. Shareholders who purchased Zynex stock based on allegedly fraudulent financial representations could file securities fraud claims. Insurance companies that paid improper claims may pursue reimbursement through civil suits.
Regulatory agencies including the Food and Drug Administration and the Centers for Medicare and Medicaid Services may also impose additional penalties or restrictions. These administrative actions operate independently of criminal proceedings and could further impact both the company and individuals involved.
Sources and References
DR: Dansk rigmand anholdt af FBI: Nu erkender hans selskab milliardsvindel
